PHARMACOKINETICS

- ASTX660 AUC increased in a dose-proportional manner in the dose range of 15 to 180 mg, and supra-proportionally above 180 mg.
- Accumulation (~2-fold) in AUC exposures was observed on Cycle 1 Day 7 (C1D7) vs Cycle 1 Day 1 (C1D1), minimal for Cmax.
- At the clinical RP2D of 180 mg, ASTX660 AUC exposures reached the target active range from preclinical models.

ASTX660 PK profile

- Dose escalation from 15 mg to 210 mg.
- AUC increased in a dose-dependent manner.
- Cmax reached at 120 minutes.
- Tmax varied from 1-2 hours.
- No significant accumulation observed.

CONCLUSIONS

- ASTX660 administered orally in a intermittent (7 days on/7 days off) schedule demonstrated a manageable safety profile.
- 180 mg dose was identified as the RP2D. This dose was well tolerated, achieved target therapeutic exposure and demonstrated biological and preliminary clinical activity.
- Engagement to Phase 2 cohorts in lymphoma and other selected cancers is ongoing (NCT02565423).

REFERENCES